38 related articles for article (PubMed ID: 24714722)
21. Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma.
Digifico E; Erreni M; Mannarino L; Marchini S; Ummarino A; Anfray C; Bertola L; Recordati C; Pistillo D; Roncalli M; Bossi P; Zucali PA; D'Incalci M; Belgiovine C; Allavena P
Front Immunol; 2023; 14():1116430. PubMed ID: 37398648
[TBL] [Abstract][Full Text] [Related]
22. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
Budde LS; Hanna NH
Expert Rev Anticancer Ther; 2004 Jun; 4(3):361-8. PubMed ID: 15161435
[TBL] [Abstract][Full Text] [Related]
23. Osteopontin: its potential role in cancer of children and young adults.
Karpinsky G; Fatyga A; Krawczyk MA; Chamera M; Sande N; Szmyd D; Izycka-Swieszewska E; Bien E
Biomark Med; 2017 Apr; 11(4):389-402. PubMed ID: 28326824
[TBL] [Abstract][Full Text] [Related]
24. Osteopontin/secreted phosphoprotein-1 harnesses glial-, immune-, and neuronal cell ligand-receptor interactions to sense and regulate acute and chronic neuroinflammation.
Yim A; Smith C; Brown AM
Immunol Rev; 2022 Oct; 311(1):224-233. PubMed ID: 35451082
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors-Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment.
Yoshikawa Y; Kuribayashi K; Minami T; Ohmuraya M; Kijima T
Front Oncol; 2020; 10():554570. PubMed ID: 33381446
[TBL] [Abstract][Full Text] [Related]
26. Osteopontin (OPN)/SPP1: from its biochemistry to biological functions in the innate immune system and the central nervous system (CNS).
Lin EY; Xi W; Aggarwal N; Shinohara ML
Int Immunol; 2023 Apr; 35(4):171-180. PubMed ID: 36525591
[TBL] [Abstract][Full Text] [Related]
27. Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight.
Lamort AS; Giopanou I; Psallidas I; Stathopoulos GT
Cells; 2019 Aug; 8(8):. PubMed ID: 31382483
[TBL] [Abstract][Full Text] [Related]
28. Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed.
Takeuchi S; Seike M; Noro R; Soeno C; Sugano T; Zou F; Uesaka H; Nishijima N; Matsumoto M; Minegishi Y; Kubota K; Gemma A
Int J Oncol; 2014 Jun; 44(6):1886-94. PubMed ID: 24714722
[TBL] [Abstract][Full Text] [Related]
29. Pemetrexed therapy for malignant pleural mesothelioma.
Puto K; Garey JS
Ann Pharmacother; 2005 Apr; 39(4):678-83. PubMed ID: 15755794
[TBL] [Abstract][Full Text] [Related]
30. Second-line treatment for malignant pleural mesothelioma.
Ceresoli GL; Zucali PA; Gianoncelli L; Lorenzi E; Santoro A
Cancer Treat Rev; 2010 Feb; 36(1):24-32. PubMed ID: 19879055
[TBL] [Abstract][Full Text] [Related]
31. The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
Boons CC; VAN Tulder MW; Burgers JA; Beckeringh JJ; Wagner C; Hugtenburg JG
Anticancer Res; 2013 Sep; 33(9):3553-61. PubMed ID: 24023280
[TBL] [Abstract][Full Text] [Related]
32. Pemetrexed in malignant pleural mesothelioma.
Gatzemeier U
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):26-31. PubMed ID: 15655933
[TBL] [Abstract][Full Text] [Related]
33. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
